ClinicalTrials.gg
RecruitingNCT06184100Updated Dec 9, 2024

Virtual Self-Management Program for JIA

An interventional study of Virtual Self-Management Program (SMP) and No Intervention in Juvenile Idiopathic Arthritis, sponsored by University of Calgary. Recruiting at 1 site in Canada. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by University of Calgary · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Arthritis, Juvenile with a site in Canada — 13 open to participants now, 15 under way, 2 of them phase 3. Arthritis, Juvenile · Canada.

Planned enrollment
19th of 47
100 · median 74
Started
2023
with 4 others
No phase
20 of 53
6 open now
Primary completion
2025-12
later than 2 of 14 live
Registered
47th of 53
by date

Among the 53 studies in Arthritis, Juvenile with a site in Canada, this one is the 19th largest by planned enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2023, is one of 20 with no phase, reaches primary completion later than 2 of the 14 other live ones, and was the 47th registered.

Arthritis, Juvenile

367 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

13 of the 53 studies in Arthritis, Juvenile with a site in Canada are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Arthritis, Juvenile with a site in Canada, or all of them as a file.
02

Study summary

The aim of this project is to conduct a pilot randomized controlled trial (RCT) to evaluate the feasibility and preliminary effectiveness of a virtual group based self-management program (SMP) in adolescents with JIA across different provinces compared to a wait-list control group receiving only standard of care.

Participants in the SMP group will partake in four 60-90 minute group sessions conducted over 8 weeks. The intervention is a multifaceted program that includes JIA disease education, self-management strategies, and peer support. Both the interventional and control group will be asked to complete baseline and post-test measures.

Participants in the control group will be offered the SMP after completion of the post-control outcome measures.

Read the detailed description

A pilot RCT will be conducted to evaluate the feasibility and preliminary effectiveness comparing the SMP intervention group with a wait-list control group receiving usual care. A total of 100 participants with confirmed JIA (ages 12 to 17) will be recruited from five Canadian pediatric rheumatology centres of different provinces and randomized in a 1:1 ratio to the control or intervention groups. Adolescents in the intervention group will receive the virtual SMP program in addition to standard of care. The intervention is a multifaceted program that includes JIA disease education, self-management strategies, and peer support. Four 60-90- minute sessions will be conducted over eight weeks with a group size of 4-6 participants. Both groups will receive usual care. Participants in the control group will be offered the SMP after completion of the post-control outcome measure. If participants choose to enroll in the SMP, the participants will be asked to complete outcome measures a second time upon completion of the program.

The primary objective is feasibility outcome that will be measured as adherence with the SMP Program (defined as 80% completion). Other feasibility outcomes will include:

(A) recruitment and withdrawal rates (>80% recruitment rate and \<80% withdrawal); (B) proportion of completed questionnaires (C) engagement and satisfaction with the SMP program as measured through a semi-structured virtual interview with the participants following involvement in the SMP; (D) intervention fidelity (consistent content and technology delivery).

The secondary objective on preliminary effectiveness includes completion of five validated and reliable patient-reported outcome measures at two-time points: perceived ability to manage JIA (self-management), pain interference, self-efficacy, health-related quality of life (HRQL) and transition readiness. These questionnaires will include:

(A) Medical Issues, Exercise, Pain, and Social Support Questionnaire (MEPS), (B) Children's Arthritis Self-Efficacy Scale (CASES), (C) Pediatric Quality of Life Inventory 3.0 Rheumatology - Teen Module (Peds QL, (D) PROMIS Pediatric Pain Interference Scale (PROMIS) and RACER (Readiness for Adult Care in Rheumatology). Descriptive statistical methods and non-parametric tests will be used to analyze the data.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

Keywords

  • Virtual
  • Education
  • Clinical Trial
  • JIA
  • Self-management Program
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adolescents between the ages of 12 and 17
  2. Confirmed diagnosis within 2 years according to the International League of Associations for Rheumatology JIA classification criteria (2)
  3. Followed in one of the pediatric rheumatology clinics participating in the RCT
  4. Able to access the Internet on a computer
  5. Willing and able to complete online measures

Exclusion criteria

Exclusion Criteria:

  1. Insufficient English reading and speaking skills
  2. Untreated psychiatric or comorbid disorders or major cognitive impairments leading to inability to understand materials and participate in the SMP group activities.
  3. Other chronic conditions such as other disease, neurologic, orthopedics or other systems disorder (e.g. heart, kidney) that might influence outcome assessments
  4. Past participation in the last year or participating in another peer-support or self-management program
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    SMP Program with Standard Care

    four 60-90 minute virtual educational sessions over 8 weeks with a group of 4-6 participants

    Other: Virtual Self-Management Program (SMP)

  • Active comparator
    Standard Care Only

    Standard of care(no formal education program similar to SMP) and placed on 8-week waitlist for optional intervention.

    Other: No Intervention

Interventions

  • OtherVirtual Self-Management Program (SMP)

    Four sessions, 60-90 minutes each, will be conducted over eight weeks with a group size of 4-6 participants via videoconferencing platforms such as Zoom or Microsoft Teams. Each session will include Power Point delivered presentations, interactive activities, and group discussions. This is a multifaceted program that includes JIA disease education, self-management strategies, and peer support.

  • OtherNo Intervention

    No intervention. Participant only receives standard of care.

06

What researchers measure

Primary outcomes

  1. Program Adherence Rates (feasability)

    The primary objective is feasibility outcome that will be measured as adherence with the SMP Program. This is defined as Proportion of completed questionnaires (defined as 80% when all measures are completed) at baseline and 8 weeks post-randomization in both groups along with recruitment and withdrawal rates. (\>80% recruitment rate and \<80% withdrawal)

    Time frame: 3 months

  2. Satisfaction of Program

    Satisfaction with the SMP as measured through a semi-structured virtual interview with the participants following involvement in the SMP to capture participants' experience.

    Time frame: 3 months

  3. Intervention fidelity

    We are looking at consistent content and technology delivery. This will be assessed by i) Observational checklists ii) qualitative analysis of recorded video sessions after 2, 4 and at completion of all sessions by each facilitator to ensure sessions are consistently delivered and as planned.

    Time frame: 3 months

Secondary outcomes

  1. Understanding of JIA

    The medical issues, exercise, pain, and social-support \[MEPS\] questionnaire is a measure for perceived ability (e.g., knowledge, skill, behavior, attitudes, and self-efficacy) to manage JIA .

    Time frame: 3 months

  2. Understanding of Arthritis Self Efficacy

    The Children's Arthritis Self-Efficacy Scale is a validated (e.g., concurrent validity, construct validity) and reliable (e.g., internal consistency) measure used for arthritis self-efficacy.

    Time frame: 3 months

  3. Quality of Life for Teens

    The Pediatric Quality of Life Inventory 3.0 Rheumatology Teen Module is a validated (e.g. construct validity) and reliable (e.g., internal consistency) measure used for pediatric rheumatology specific health related quality of life in children aged 13-18

    Time frame: 3 months

  4. Physical Pain Level

    The PROMIS Pediatric Pain Interference Scale is validated and reliable (e.g., internal consistency) measure for pain behavior in children aged 8-17

    Time frame: 3 months

  5. How Prepared the patient feels for Adult Care

    Readiness for Adult Care in Rheumatology (RACER) questionnaire a reliable and validated instrument used to assess transition readiness in adolescents with JIA.

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2025, 24 months after the start.

Of 53 non-industry interventional studies with no phase under Arthritis, Juvenile, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's planned 24 months is above that.

Counting every sponsor, half of 56 studies reached it within 14 months; a quarter within 8 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2023
First posted
Dec 28, 2023
StartActual
Dec 13, 2023
Primary completionEst.
Dec 2025
CompletionEst.
Mar 2026
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06184100
Responsible party
Sponsor
First posted
Dec 28, 2023
Start date
Dec 13, 2023
Primary completion
Dec 2025 (estimated)
Completion
Mar 2026 (estimated)
Last update
Dec 9, 2024

Study contacts

Heinrike Schmeling, MD, PhD
Contact
SchmelingResearch@albertahealthservices.ca
403-955-7698
Jessica Booth, BSc
Contact
SchmelingResearch@albertahealthservices.ca
403-955-3194

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion